I think I can answer the first questsion SF.....you asked:

"1.  What is the expected deal larger than?   Previous deals like Hepalink?   Or larger than a deal that was on the table before from perhaps another party"?

Okay....larger than what?  I think from Zack's update its larger than the $10 million just raised, and sufficient to fund operations and support the anticipated burn rate of $2 to $2.5 million per month until sometime in 2019.  

To wit:

On June 9th, Resverlogix announced that it had confirmed CAD$10 million in demand for equity shares in an overnight offering marketed to Canadian investors. We anticipate the final details regarding net proceeds and shares issued will be available in the next week or two. The CAD$10 million capital raise should be sufficient to provide the flexibility to negotiate a larger licensing or first right of refusal deal that will support clinical trials and operations until a new drug application can be submitted to the FDA, which we anticipate occurring in 2019. Based on our conversations with management and the limited level of capital targeted in last week s announcement, we anticipate that a larger deal is close at hand which will provide enough cash to fund the $2.0 to $2.5 million per month in anticipated cash burn.